{
    "id": 3389,
    "fullName": "HGF over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HGF over exp indicates an over expression of the Hgf protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3082,
        "geneSymbol": "HGF",
        "terms": [
            "HGF",
            "DFNB39",
            "F-TCF",
            "HGFB",
            "HPTA",
            "SF"
        ]
    },
    "variant": "over exp",
    "createDate": "02/26/2015",
    "updateDate": "07/02/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11350,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of JNJ-38877605 and Erbitux (cetuximab) inhibited growth of colorectal cancer cell lines over expressing HGF in culture, and induced tumor regression in xenograft models (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 5951,
                "therapyName": "Cetuximab + JNJ 38877605",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of JNJ-38877605 and Vectibix (panitumumab) inhibited growth of colorectal cancer cell lines over expressing HGF in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 5952,
                "therapyName": "JNJ 38877605 + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11349,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of HGF conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11346,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of HGF conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture and in xenograft models (PMID: 23729478).",
            "molecularProfile": {
                "id": 3198,
                "profileName": "HGF over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1775,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-701 and Iressa (gefitinib) combination treatment inhibited growth of non-small cell lung cancer cell lines harboring EGFR activating mutations and over expressing HGF in culture and in cell line xenograft models which were resistant to Iressa (gefitinib) as monotherapy (PMID: 20716641).",
            "molecularProfile": {
                "id": 3199,
                "profileName": "EGFR act mut HGF over exp"
            },
            "therapy": {
                "id": 2179,
                "therapyName": "Gefitinib + TAK-701",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2036,
                    "pubMedId": 20716641,
                    "title": "TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20716641"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8238,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uveal melanoma cells cultured in a condition medium that over expresses HGF and NRG1 resulted in resistance to Mekinist (trametinib) in culture, however, the addition of Xalkori (crizotinib) led to restored sensitivity (PMID: 25952648).",
            "molecularProfile": {
                "id": 26204,
                "profileName": "HGF over exp NRG1 over exp"
            },
            "therapy": {
                "id": 4480,
                "therapyName": "Crizotinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6584,
                    "pubMedId": 25952648,
                    "title": "Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25952648"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8236,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of NRG1 and HGF in uveal melanoma cells treated with Mekinist (trametinib) led to increased Akt activity, which was reduced when additionally treated with MK2206 in culture (PMID: 25952648).",
            "molecularProfile": {
                "id": 26204,
                "profileName": "HGF over exp NRG1 over exp"
            },
            "therapy": {
                "id": 4653,
                "therapyName": "MK2206 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6584,
                    "pubMedId": 25952648,
                    "title": "Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25952648"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8234,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment of uveal melanoma cells with Mekinist (trametinib) in culture resulted in resistance, which was mediated by the over expression of HGF and NRG1 (PMID: 25952648).",
            "molecularProfile": {
                "id": 26204,
                "profileName": "HGF over exp NRG1 over exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6584,
                    "pubMedId": 25952648,
                    "title": "Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25952648"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8237,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uveal melanoma cells cultured in a condition medium that over expresses HGF and NRG1 resulted in resistance to Mekinist (trametinib) in culture, however, the addition of Tykerb (lapatinib) led to restored sensitivity (PMID: 25952648).",
            "molecularProfile": {
                "id": 26204,
                "profileName": "HGF over exp NRG1 over exp"
            },
            "therapy": {
                "id": 4668,
                "therapyName": "Lapatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6584,
                    "pubMedId": 25952648,
                    "title": "Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25952648"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3198,
            "profileName": "HGF over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3199,
            "profileName": "EGFR act mut HGF over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26204,
            "profileName": "HGF over exp NRG1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}